Avalon GloboCare Corp. (NASDAQ:CHGA) Shares Shorted: Short Interest Up 156.5% in September

Avalon GloboCare Corp. (NASDAQ:CHGA) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totaling 85,127 shares, a growth of 156.5% from the September 15th total of 33,188 shares. Based on an average daily trading volume, of 3,006,731 shares, the days-to-cover ratio is presently 0.0 days. Currently, 9.1% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Avalon GloboCare from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, August 24th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Avalon GloboCare currently has a consensus rating of “Sell”.

Avalon GloboCare Price Performance

Shares of CHGA stock traded up $0.08 during trading hours on Monday, reaching $2.10. The stock had a trading volume of 151,867 shares, compared to its average volume of 362,469. The firm has a market capitalization of $2.35 million, a PE ratio of -0.15 and a beta of -0.08. The firm has a 50-day simple moving average of $3.38 and a 200-day simple moving average of $5.96. Avalon GloboCare has a twelve month low of $1.79 and a twelve month high of $48.00.

Avalon GloboCare (NASDAQ:CHGA) last issued its quarterly earnings data on Friday, August 14th. The company reported ($2.80) earnings per share (EPS) for the quarter.

About Avalon GloboCare

Avalon GloboCare Corp. is a biotechnology company focused on developing cell-based and regenerative medicine technologies. Its work has included cellular immunotherapies, exosome-based products and other platforms intended to support the treatment of cancer and other serious medical conditions.

The company has also pursued activities involving cell and gene therapy development, biobanking and related laboratory services. Avalon GloboCare has described its business as spanning research, product development and potential commercialization through collaborations and strategic partnerships.

Avalon GloboCare was founded in the United States and has historically been associated with operations in New Jersey.